

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 June 2020 (11.06.2020)



(10) International Publication Number
WO 2020/115048 A1

(51) International Patent Classification:
C07K 14/435 (2006.01) C07K 14/605 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:
PCT/EP2019/083506

(22) International Filing Date:
03 December 2019 (03.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18209896.2 03 December 2018 (03.12.2018) EP
19176739.1 27 May 2019 (27.05.2019) EP

(71) Applicant: **ANTAG THERAPEUTICS APS** [DK/DK];
Ole Maaloes Vej 3, 2200 Copenhagen N (DK).

(72) Inventors: **SPARRE-ULRICH, Alexander, Hovard**;
Nansensgade 3, 1th, 1366 Copenhagen K (DK).
SIVERTSEN, Bjørn, Behrens; Halbsdansgade 11 st th,
2300 Copenhagen S (DK). **RIBER, Ditte**; Degnemose Allé
64, 2700 Bronshøj (DK). **ROSENKILDE, Mette, Marie**;
Ole Olsens Allé 30, 2900 Hellerup (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K
(DK).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: MODIFIED GIP PEPTIDE ANALOGUES

(57) Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP) -derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are modified by comprising one or more individual amino acid substitutions and are fatty acid conjugated with/without a linker, so to have improved antagonistic activity and improved pharmacokinetic profile.



WO 2020/115048 A1